IBIO 200 is a virus-like particle (VLP) based vaccine being developed by iBio and Beijing CC Pharming using iBio's FastPharming System™, for the prevention of COVID-2019 infections. The vaccine is designed to maximise uptake by antigen presenting cells in order to increase the overall immune response. A SARS-CoV-2 derived antigen is fused to a self-assembling protein partner to generate the VLP. The antigen is displayed in a repetitive structure and geometry, and the particle is decorated with oligomannose molecules to resemble the structure of a naturally occurring virus.FastPharming System™ combines vertical farming, automated hydroponics, and glycan engineering technologies wherein plants are used as bioreactors for development of vaccines and biologics. Preclinical development is underway in the US. Early research is underway in China.
In February 2020, iBio and Beijing CC Pharming entered into a collaboration to develop and test a new coronavirus vaccine to be manufactured using iBio’s FastPharming System™. Financial terms of the deal are undisclosed.  
In April 2020,iBio signed a Memorandum of Understanding (MOU) with the Infectious Disease Research Institute (IDRI) to support iBio’s SARS-CoV-2 Virus-Like Particle (VLP) vaccine development. The MOU calls for iBio and IDRI to establish a separate, additional agreement within the next 60 days if iBio opts to include one of IDRI’s adjuvants in the COVID-19 vaccine development programme (IBIO 200). The MoU integrates IDRI into iBio’s collaboration with the Texas A&M University System to create a strong partnership that brings deep experience and advanced technologies and capabilities to the task of moving IBIO 200 into the clinic. 
In June 2016, Texas A&M University System entered into a development agreement with iBio for collaborative program in plant-produced pharmaceuticals. The collaboration will use the research and development resources of TAMUS with the commercial therapeutics and vaccine development and manufacturing capabilities of iBio. 
Key Development Milestones
In March 2020, iBio initiated preclinical studies of IBIO 200 at the Texas A&M University System (“TAMUS”) laboratories as part of the Master Joint Development Agreement established between iBio and TAMUS  .
As of February 2020, plant based coronavirus vaccine is in early research for the treatment of COVID-2019 infections  .
In March 2020, iBio filed four provisional patent applications number US9 012 199 with the U.S. Patent and Trademark Office (US PTO), for Virus Like Particle (VLP) platform technology and lichenase carrier immunostimulatory (“LickM”) adjuvant technology. The applications also cover vaccine manufacturing method using FastPharming system™  .